Andrean L. Simons

Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.

2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells.

Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging.

2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress.

Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism.

Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells.

Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells.

Glucose deprivation-induced metabolic oxidative stress and cancer therapy.

Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4.

Regulation of pancreatic cancer growth by superoxide.

Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism.

The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation.

NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.

EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.

MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.

2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.

Impact of Nuclear Interleukin-1 Alpha and EGFR Expression on Recurrence and Survival Outcomes in Oral Squamous Cell Carcinomas.

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.

immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy.

The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent.

Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model.

Ketogenic Diet with Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma: Preclinical and Phase 1 Trial Results.